So, a lot of questions I think in the questions. I think as far as treatment time - but first of all, pain score, as it relates to the presentations that were presented at ASLMS by Dr. Katz and Dr. Bass on flank and abdomen, the average pain score was 3.7 out of 10, which is very consistent with what other devices have shown on the market. So that - we are very pleased with that because one of the areas of concern with introducing a hypothermic approach, using heat as the main modality to destroy adipose tissue, which we believe is the best way to go is, how do you manage the pain with the patient. We also come up with a proprietary approach to getting the temperature up, which is very important to achieve, to destroy adipose tissue, and sustaining that over the treatment period. The beauty of heat is you can get to that temperature much, much quicker than you can with cold technology. So that in and of itself has allowed us to reduce our treatment time significantly. For your question on our device as it relates to being able to treat multiple areas, yes, that's one of the beauties of the design around this technology that with other technologies you are buying an applicator per anatomical area, with our technology, once we unveil it, it will be much clearer to the consumer that you are able to have a very versatile applicator system that comes with the technology, that allows you to manipulate that or positioning it based on - or position these applicators based on the anatomical areas you want to treat. For example, the flanks, the abdomen. The flanks, we have to treat both the right and left side of the body. Depending on the size of the patient, we could treat, let's say, an average patient's flank, both sides at the same time where our competition has to treat one side at a time. Our treatment time could end up being 25 minutes for that patient to come in and leave; with competitive technology that would be 2 hours. So that's a huge advantage we believe, and we know that just from our focus groups. The doctors really look to optimize their lanes, their rooms, and the more one patient sits in there utilizing that time, less revenue is generated. So if we can demonstrate the throughput, which we know we can, that should be very important. So we are very pleased with both of those abstract; presentations, they were very well received by the audience, and we've given more color now on how our technology works from a scientific and clinical perspective.